Expression of E-cadherin in primary prostate cancer: Correlation with clinical features

British Journal of Urology

Volumn 81, Issue 3, 1998, Pages 406-412

  Kuczyk, M ^a,c   Serth, J ^a   Machtens, S ^b   Bokemeyer, C ^a   Bathke, W ^b   Stief, C ^a   Jonas, U ^a  

^a UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^b UNIVERSITY OF TÜBINGEN   (Germany)

^c HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

Clinical prognosis; E cadherin; Expression; Prostate cancer; Radical prostatectomy

Indexed keywords

ACID PHOSPHATASE PROSTATE ISOENZYME; PROSTATE SPECIFIC ANTIGEN; UVOMORULIN;

ADULT; AGED; ARTICLE; CANCER STAGING; CANCER SURVIVAL; FOLLOW UP; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; PROSTATECTOMY;

ADENOCARCINOMA; AGE FACTORS; AGED; CADHERINS; DISEASE-FREE SURVIVAL; FOLLOW-UP STUDIES; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; NEOPLASM PROTEINS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROGNOSIS; PROSTATIC NEOPLASMS;

EID: 0031819363     PISSN: 00071331     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1464-410X.1998.00539.x     Document Type: Article

References (29)

1. Boring CC, Squires TS, Tong T. Cancer statistics. ÇA Cancer J Clin 1993: 4: 7-26
2. Adolfsson J. Carstensen T. Lowhagen T. Deferred treatment in localised prostate cancer. Br / Urol 1992: 69: 183-7
3. George NJR. Natural history of localised prostate cancer managed by conservative therapy alone. iMncet 1988: i: 494-7
4. Johansson JE. Adami HO. Andersson SO. Bergström R, Holmberg L, Krusemo ÜB. High 10 year survival rate in patients with early untreated prostate cancer. )AMA 1992: 267: 2191-6
5. Isaacs WB, Bova GS. Morton RA. Bussemakers M], Brooks JD. Ewing CM. Molecular biology of prostate cancer. Semin Oncol 1994; 21: 514-21
6. Debruyne FM. Collins VP. Van Dekken H et al. Cytogenetics of prostate cancer. Consensus Conference on Diagnosis and Prognostic Parameters in localized prostate cancer. Scand } Urol Nephrol 1994: 162: 65-71
7. Shimazui T. Schalken JA, Giroldi LA et al. Prognostic value of cadherin-associated molecules (alpha-, beta-, and gamma-catenins and p!20cas) in bladder tumors. Cancer Res 1996: 56: 4154-8
8. Banks RE. Porter WH. Whelan P. Smith PH. Selby PJ. Soluble forms of the adhesion molecule E-cadherin in urine. / Clin Pathol 1995: 48: 179-80
9. Terpe H-J, Zörb Ch Finke L. Schlag P. Integrins and E-cadherin expression-a way for the better understanding of the biological behaviour of colorectal cancer. Onkologie 1997: 20: 48-52
10. Pignatelli M. Liu D. Nasim MM. Stamp GWH, Hirano S. Takeichi M. Morphoregulatory activities of E-cadherin and beta-1 integrins in colorectal tumour cells. Br ] Cancer 1992; 66: 629-34
11. Cheng L. Nagabhushan M. Pretlow TP. Amini SB. Pretlow TG. Expression of E-cadherin in primary and metastatic prostate cancer. Am ] Pathol 1996; 148: 1375-80
12. Umbas R. Isaacs WB. Bringuier PP et al. Decreased E-cadherin expression is associated with a poor prognosis in patients with prostate cancer. Cancer Res 1994: 54: 3929-33
13. Me William LJ. Knox WE, Hill C. George NJR. E-cadherin expression fails to predict progression and survival in prostate cancer. / Urol 1996: 155. part; 2: 821A
14. Tamm I. Cardinale I. Kikuchi T. Krueger JG. E-cadherin distribution in interleukin 6-induced cell-cell separation of ductal breast carcinoma cells. Proc Natl Acad Sei USA 1994; 91: 4338-42
15. 5 Giroldi LA. Bringuier PP. Schalken JA. Defective E-cadherin function in urological cancers: clinical implications and molecular mechanisms. Invasion Metastasis 1994: 14: 1-6
16. Bringuier PP, Umbas R, Schaafsma HE, Karthaus HEM. Debruyne FMJ. Schalken JA. Decreased E-cadherin immunoreactivity correlates with poor survival in patients with bladder tumors. Cancer Res 1993: 53: 3241-5
17. Cohen MB, Griebling TL, Ahaghotu CA. Rokhlin OW. Ross JS. Cellular adhesion molecules in urologie malignancies. Am ] Clin Pathol 1997; 107: 56-63
18. Boyer B. Dufour S. Thiery JP. E-cadherin expression during the acidic FGF-induced dispersion of a rat bladder carcinoma cell line. Exp Cell Res 1992: 201: 347-57
19. Edelmann GM. Gallin WJ, Delouvee A, Cunningham BA. Thiery JP. Early epochal maps of two different cell adhesion molecules. Proc Natl Acad Sei USA 1983; 80: 4384-8
20. Vestweber D, Kemler R. Rabbit antiserum against a purified surface glycoprotein decompacts mouse preimplantation embryos and reacts with specific adult tissue. Exp Cell Res 1984; 152: 168-78
21. Takeichi M. Cadherin cell adhesion receptor as a morphogenetic regulator. Science 1991; 251: 1451-5
22. Bussemakers MJ, Giroldi LA, Van Bokhoven A. Schalken JA. Transcriptional regulation of the human E-cadherin gene in human prostate cancer cell lines: characterization of the human E-cadherin gene promotor. Biochem Biophys Res Commun 1994; 203: 1284-90
23. Bussemakers MJG. Schalken JA. The role of cell adhesion molecules and proteases in tumor invasion and metastasis. World JUrol 1996; 14: 151-6
24. Gingrich JR, Barrios RJ, Morton RA et al. Metastatic prostate cancer in a transgenic mouse. Cancer Res 1996; 56: 4096-102
25. Shi S-R, Key ME, Kalra KL. Antigen retrieval in formalinfixed, paraffin-embedded tissues: an enhancement method for immunohistochemical staining based on microwave oven heating of tissue sections. / Histochem Cytochem 1991; 39: 741-8
26. Bringuier PP, Umbas R, Schaafsma HE. Karthaus HF, Debruyne FM, Schalken JA. Decreased E-cadherin immuno-reactivity correlates with poor survival in patients with bladder tumors. Cancer Res 1993; 53: 3241-5
27. Kuczyk MA, Serth J, Bokemeyer C, Höfner K, Allhoff EP, Jonas U. Immunohistochernical detection of cathepsin D expression in prostate cancer. Oncol Rep 1994; 1: 1247-51
28. Shurbaji MS, Kalbfleisch JH, Thurmond TS. Immunohistochernical detection of p53 protein as a prognostic indicator in prostate cancer. Hum Pathol 1995; 26: 106-9
29. Bauer JJ, Sesterhenn IA, Mostofl FK, McLeod DG, Srivastava S, Moul JW. Elevated levels of apoptosis regulator proteins p53 and bcl-2 are independent prognostic biomarkers in surgically treated clinically localized prostate cancers. / Urol 1996; 155: 964A